Eylea HD sales up in Q3 but Regeneron still losing market share
5 days ago · The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye ...
Regeneron shares drop as higher-dose Eylea drug misses sales …
5 days ago · The higher-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between injections for patients. Regeneron's total revenue of $3.72 billion beat ...
US FDA approves two biosimilars for blockbuster eye drug Eylea
May 20, 2024 · The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye...
Regeneron fends off Viatris' Eylea biosimilar with patent win
Dec 29, 2023 · A West Virginia judge ruled that Viatris' proposed biosimilar violates a Regeneron patent that covers ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein...
Regeneron’s Eylea biosimilar fight heats up - STAT
Sep 24, 2024 · Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
EYLEA® (aflibercept) Injection Approved as the First …
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA. ROP is a leading cause of childhood blindness worldwide. EYLEA now approved to treat five …
Regeneron Earnings: Biosimilar Eylea Introduces ... - Morningstar
6 days ago · Sales for the Eylea franchise were $2.5 billion in the quarter, up 4% year on year; $392 million of that was Eylea high-dose sales in the US. Roche’s Vabysmo has experienced an impressive ramp ...
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg ...
TARRYTOWN, N.Y., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD ® (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME).
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for …
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy...
FDA approves first interchangeable biosimilars to Eylea to treat ...
FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept). Aflibercept products work by inhibiting vascular endothelial …